These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 8948369

  • 1. CD8+ lymphocyte responses to antiretroviral therapy of HIV infection.
    Carr A, Emery S, Kelleher A, Law M, Cooper DA.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Dec 01; 13(4):320-6. PubMed ID: 8948369
    [Abstract] [Full Text] [Related]

  • 2. Anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) T-lymphocyte reactivity during combination antiretroviral therapy in HIV-1-infected patients with advanced immunodeficiency.
    Rinaldo CR, Huang XL, Fan Z, Margolick JB, Borowski L, Hoji A, Kalinyak C, McMahon DK, Riddler SA, Hildebrand WH, Day RB, Mellors JW.
    J Virol; 2000 May 01; 74(9):4127-38. PubMed ID: 10756025
    [Abstract] [Full Text] [Related]

  • 3. Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages.
    Sleasman JW, Nelson RP, Goodenow MM, Wilfret D, Hutson A, Baseler M, Zuckerman J, Pizzo PA, Mueller BU.
    J Pediatr; 1999 May 01; 134(5):597-606. PubMed ID: 10228296
    [Abstract] [Full Text] [Related]

  • 4. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team.
    Nachman SA, Stanley K, Yogev R, Pelton S, Wiznia A, Lee S, Mofenson L, Fiscus S, Rathore M, Jimenez E, Borkowsky W, Pitt J, Smith ME, Wells B, McIntosh K.
    JAMA; 2000 Jan 26; 283(4):492-8. PubMed ID: 10659875
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
    Paris D, Ledergerber B, Weber R, Jost J, Flepp M, Opravil M, Ruef C, Zimmerli S.
    AIDS Res Hum Retroviruses; 1999 Dec 10; 15(18):1631-8. PubMed ID: 10606086
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients.
    Vidal C, García F, Gatell JM, Leal M, Clotet B, Pumarola T, Miró JM, Mallolas J, Ruiz L, Cruceta A, Tortajada C.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Sep 01; 19(1):55-60. PubMed ID: 9732070
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
    Albrecht MA, Hughes MD, Liou SH, Katzenstein DA, Murphy R, Balfour HH, Para MF, Valdez H, Hammer SM, ACTG 303 Study Team.
    AIDS Res Hum Retroviruses; 2000 Sep 20; 16(14):1337-44. PubMed ID: 11018853
    [Abstract] [Full Text] [Related]

  • 14. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep 20; 10 Suppl 1():S57. PubMed ID: 8595510
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine.
    Michelet C, Bellissant E, Ruffault A, Arvieux C, Delfraissy JF, Raffi F, Bazin C, Renard I, Sébille V, Chauvin JP, Dohin E, Cartier F.
    Clin Pharmacol Ther; 1999 Jun 20; 65(6):661-71. PubMed ID: 10391672
    [Abstract] [Full Text] [Related]

  • 17. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
    Gray CM, Schapiro JM, Winters MA, Merigan TC.
    AIDS Res Hum Retroviruses; 1998 May 01; 14(7):561-9. PubMed ID: 9591710
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P, Srasuebkul P, Hassink E, Mahanontharit A, Samor T, Ruxrungtham K, Lange J, Cooper D, Phanuphak P.
    HIV Med; 2005 Mar 01; 6(2):122-8. PubMed ID: 15807718
    [Abstract] [Full Text] [Related]

  • 20. Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed.
    Bellman PC.
    AIDS; 1998 Jul 30; 12(11):1333-40. PubMed ID: 9708413
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.